Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Appl Thromb Hemost
Egile Nagusiak: Stevens, Victoria M., Trujillo, Toby, Mueller, Scott W., MacLaren, Robert, Reynolds, Paul M., Kiser, Tyree H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019392/
https://ncbi.nlm.nih.gov/pubmed/31876159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029619896619
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak